Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

In this page

Clinical Trial

NCT04435366 Completed
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase 3
Interventional

Disease

Disease type

Other

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

22/06/2020

Closing date

22/08/2023

Inclusion criteria :

More

Exclusion criteria :

More

Funding

private

Members involved

Others investigators

Dr Mikk Pauklin

Representative

Estonia

Anterior Segment Rare Eye Diseases (WG4)
See more

Dr Laura Mauring

Substitute

Estonia

Genetic Diagnostics (TWG6), Pediatric Ophthalmology Rare Diseases (WG3), Retinal Rare Eye Diseases (WG1)
See more

Dr Yannick Lemer

Representative

France

See more

Pr Frank Holz

Representative

Germany

See more

Dr Philipp Herrmann

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Pr Martin Spitzer

Representative

Germany

Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Johannes Birtel

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Claudia Priglinger

Representative

Germany

See more

Dr Katarina Stingl

Representative

Germany

Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Dr Susanne KOHL

Substitute

Germany

Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Dr Giacomo Maria Bacci

Substitute

Italy

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), Pediatric Ophthalmology Rare Diseases (WG3), Retinal Rare Eye Diseases (WG1)
See more

Pr Francesca Simonelli

Representative

Italy

Genetic Diagnostics (TWG6), National Integration (TWG9), Registries & Epidemiology (TWG7), Retinal Rare Eye Diseases (WG1)
See more

Pr Francesco Testa

Substitute

Italy

Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Retinal Rare Eye Diseases (WG1)
See more

ERN EYE member investigating site

HCP : Principal investigators

Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany

Adress

Department für Augenheilkunde Tübingen Forschungsinstitut für Augenheilkunde Elfriede-Aulhorn-Str. 7

72076 Tübingen

Germany